Abiraterone in metastatic prostate cancer without previous chemotherapy Academic Article uri icon

Overview

MeSH Major

  • Androstadienes
  • Antineoplastic Combined Chemotherapy Protocols
  • Prednisone
  • Prostatic Neoplasms

abstract

  • Abiraterone improved radiographic progression-free survival, showed a trend toward improved overall survival, and significantly delayed clinical decline and initiation of chemotherapy in patients with metastatic castration-resistant prostate cancer. (Funded by Janssen Research and Development, formerly Cougar Biotechnology; ClinicalTrials.gov number, NCT00887198.).

authors

publication date

  • January 10, 2013

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3683570

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1209096

PubMed ID

  • 23228172

Additional Document Info

start page

  • 138

end page

  • 48

volume

  • 368

number

  • 2